These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888 [TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Stenman UH Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813 [No Abstract] [Full Text] [Related]
4. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Greene DR Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749 [No Abstract] [Full Text] [Related]
5. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Trpkov K Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751 [No Abstract] [Full Text] [Related]
13. Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. van der Poel HG Eur Urol; 2008 Mar; 53(3):561-2. PubMed ID: 17683855 [No Abstract] [Full Text] [Related]